Study of Apatinib in RET Fusion Positive Advanced Non-small Cell Lung Cancer
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
RET fusions are present in 1% to 2% of unselected population of non-small cell lung cancer
(NSCLC). Existing US Food and Drug Administration-approved inhibitors of RET tyrosine kinase
show promising therapeutic effects in a non-small cell lung cancer patients. Apatinib is an
oral multi-kinase inhibitors including RET fusions. This study is designed to evaluate the
safety and tolerability of Apatinib in patients with RET fusion positive advanced NSCLC.